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Background: Autochthonous hepatitis E has been observed with growing incidence in industrialized countries.
Hepatitis E virus infection causes an acute hepatitis with spontaneous resolution in the majority of cases. However,
in individual cases, hepatitis E may lead to life-threatening acute liver failure. In this report, we describe a case of
acute liver injury caused by an autochthonous hepatitis E that resolved under steroid treatment. To our knowledge,
this is the first case report describing supportive steroid monotherapy for acute liver injury due to hepatitis E.
Case presentation: A 63-year-old Caucasian male presented with acute liver injury of unknown origin. After excluding
the most prevalent causes of acute liver injury, liver histology revealed signs of immune-mediated toxic or
drug-induced liver injury. Therefore, immunosuppressive treatment with prednisolone was started. After initialization of
steroid treatment, polymerase chain reaction analyses of peripheral blood and liver tissue revealed an acute hepatitis E
virus infection (genotype 3). Under sustained steroid treatment, acute liver injury improved and hepatitis E infection
resolved.
Conclusion: Steroid treatment might be an option to prevent progress of life-threatening liver failure and liver
transplantation in patients with hepatitis E-induced acute liver injury and high-grade inflammation.
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Hepatitis E (HEV) is a single-stranded RNA-virus and
its genome comprises three overlapping open reading
frames (ORF). Four human pathogenic HEV genotypes
are represented by one serotype. Autochthonous hepa-
titis E in industrialized countries is due to HEV genotype
3 and 4. These genotypes infect both humans and ani-
mals, such as pigs, rodents and shellfish [1]. Risk factors
for clinically apparent autochthonous HEV infection are
male sex and older age [2]. Chronic alcohol consump-
tion additionally seems to promote a more severe course
of HEV infection [3]. An important differential diagnosis
for hepatitis E is drug-induced liver injury (DILI). It has
been shown that acute autochthonous HEV has been* Correspondence: m.sebode@uke.de
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unless otherwise stated.frequently misdiagnosed as DILI in the past [4], thus the
awareness for the diagnosis of hepatitis E needs to be
increased.
The diagnosis of acute HEV infection is based on the
detection of HEV RNA by polymerase chain reaction
(PCR) and/or anti-HEV IgM. Anti-HEV IgG emerges
normally in the later course of resolving hepatitis E.
Immunoassays vary in their accuracy and are not reliable
for making a proper diagnosis of acute HEV infection
[5]. Thus, confirmation of hepatitis E should rely on
highly sensitive HEV-RNA PCR out of blood or stool sam-
ples [1]. However, a recent investigation showed a variable
sensitivity for different HEV PCR assays [6]. False negative
test results may lead to undiagnosed cases with possible
severe complications [7]. As of now, no test for detection
of HEV has been approved for clinical use in the USA by
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quence, liver transplantation may be required. Most of
these fulminant HEV infections are due to endemic
genotype 1, especially in pregnant women and patients
with chronic liver disease [8,9]. In autochthonous HEV
infections caused by genotype 3, acute hepatitis usually
resolves spontaneously within 4–6 weeks [10]. However,
hepatic failure can occur as a rare complication [3]. In
case series of hepatic failure by hepatitis E genotype 1
and 3, ribavirin has successfully been used to prevent
liver transplantation [11,12].
We here report a case of acute liver injury caused by
an autochthonous HEV genotype 3 infection that re-
solved under steroid treatment.
Case presentation
A 63-year-old male was referred to our liver unit be-
cause of acute liver injury of unknown origin. One day
before admission, he presented himself at the emergency
room with a rapid onset and painless jaundice. In the
week before, he had had two episodes of chills and night
sweats and observed clinical signs of cholestasis, in par-
ticular dark urine and pale stools. In the past medical
history, the patient suffered from high blood pressure,
an asymptomatic cholecystolithiasis and colonic diver-
ticulosis. His only medication was 10 mg of bisoprolol
per day for many years. No allergies and no herbal or
over-the-counter remedies were reported. He regularly
drank 0.5 liters of beer per day. He did not smoke or use
illicit drugs. There was no history of surgery or blood
transfusions. Consumption or contact to game meat in
the last 6 months was also excluded. He was married
and had no changing sexual partners. In his family, noTable 1 Laboratory data
Variable Reference range On admission
Hemoglobin (g/dl) 14.0-17.5 15.0
White-cell count 3.8-11.0 4.6
(per mm3)
Platelet count 150-400 113
(per mm3)
International normalized ratio 2.01
Urea nitrogen (mg/dl) 8-26 13
Creatinine (mg/dl) 0.6-1.3 0.8
Bilirubin total (mg/dl) <1.2 7.7
Alkaline phosphatase (U/l) 40-129 154
Gamma-glutamyl transpeptidase (U/l) <65 312
Alanine aminotransferase (U/l) 10-50 6635
Aspartate aminotransferase (U/l) 10-50 5133
Lactate dehydrogenase (U/l) 87-241 1144
Albumin (g/l) 35-50 33autoimmune or genetic diseases were known. He was a
retired truck driver and bred poultry as a hobby.
On clinical examination, the patient was in an obese
condition with a body-weight of 100 kg. He presented
with jaundice. No clinical signs of liver cirrhosis were
detected. The abdomen was slightly tender in the right
upper quadrant and the liver was extended 4 to 5 cm
below the costal margin. An enlargement of the spleen
was not detected. There were no clinical signs of hepatic
encephalopathy.
On admission, laboratory results revealed an acute
liver injury with high transaminases (Table 1). Additional
laboratory results on admission were CRP (C reactive
protein) 26 mg/l (normal range <5 mg/l), antithrombin
III 51.8% (70-130%), ferritin 22093.0 μg/l (34–400 μg/l),
transferrin saturation 95% (16-45%), ceruloplasmin 0.30 g/l
(0.22-0,61 g/l) and ANA (antinuclear antibodies) 1:80. AMA
(antimitochondrial antibodies), SMA (smooth muscle
antibodies), LKM (liver-kidney-microsome antibodes)
and SLA/LP-(soluble liver antigen/liver pancreas antigen)
antibodies were negative. We excluded hepatotropic viral
infections, especially hepatitis A, B and C virus, as well as
cytomegalovirus, Epstein-Barr-virus, adenoviruses and her-
pes simplex virus. On the first day in our unit, an immuno-
blot for anti-HEV IgG was intermediate positive. Anti-HEV
IgM could not be detected. An initial commercial qualita-
tive PCR (Genosis, Primerdesign, Southhampton, UK) was
negative for HEV-RNA.
Abdominal ultrasound showed no signs of liver cirrho-
sis or intrahepatic masses. Ascites was absent. The gall
bladder and the biliary tract were regular. A vascular
pathology, such as portal or liver vein thrombosis, was
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opsy. On laparoscopic liver examination, retractions of
the liver surface could be detected as indication for focal
necrosis, typical for acute liver injury (Figure 1). There
was no evidence of chronic liver injury or cirrhosis. On
histopathology, an acute lobular and cholestatic hepatitis
was revealed (Figure 2). There were no typical histo-
logical signs of iron overload and steatohepatitis. Based
on liver histology, an immune-mediated toxic or drug-
induced hepatitis was favored.
The initial working diagnosis was an allergic drug-
induced acute liver injury caused by an unidentified sub-
stance. Based on distinct immune cell infiltrates in liver
biopsy and high risk of acute liver failure, an immunosup-
pressive therapy with prednisolone (1 mg per kilogram
body weight per day) was started immediately after liver
biopsy on the second day in our unit. Following chemical
response, prednisolone was reduced in a stepwise fashion
by 10 mg per week down to a daily dose of 20 mg and
then reduced in 5 mg steps per week.
Despite negative initial qualitative PCR analysis for
HEV ORF2, we suspected acute HEV infection: The pa-
tient had risk factors for acute HEV infection (age, sex,
clinical presentation) and an agent for DILI could not be
identified in repeated interviews. Therefore and because
anti-HEV IgG was intermediate positive, PCR for HEV
was repeated by two different real time PCR assays
based on the detection of ORF3 HEV (Altona Diagnos-
tics, Hamburg Germany) and a quantitative in-house
PCR [13]. Finally, both quantitative PCR analyses were
positive and HEV genotyping confirmed HEV genotype
3 infection as the reason for acute liver injury in this pa-
tient. As additional confirmation, HEV-RNA was alsoFigure 1 Laparoscopic liver examination. Retractions of the liver surfacedetected in the liver tissue by both quantitative PCR as-
says based on ORF3 target region. For viral quantifica-
tion, the new WHO standard was used and results were
normalized to IU/ml. Under sustained steroid treatment,
hepatitis E resolved adequately with rapidly declining
viral load (Figure 3). Hepatic encephalopathy did not
emerge in the further clinical course. The ALT level de-
clined to 50% of its initial value three days after starting
steroids. Besides, a 50% reduction of bilirubin was ob-
served 15 days after beginning the steroid course. Be-
cause of the benign course under sustained treatment,
we decided to continue steroids and did not add ribavi-
rin, which would have been an option for acute severe
HEV infection [11,12].
Conclusions
In this case, diagnosis of acute HEV infection was de-
layed and acute liver injury was initially diagnosed as re-
lated to an immune-mediated toxic or drug-induced
liver injury. Initial ELISA assays showed only an inter-
mediate positive reaction for anti-HEV IgG and a nega-
tive reaction for anti-HEV IgM. The latter is probably
due to a false negative result and underlines the need for
PCR analyses for making an accurate diagnosis of acute
HEV infection. Since the initial PCR analysis was also
negative for HEV, the final diagnosis needed the use of
an alternative PCR assay in this case. Interestingly, a re-
cent study indicated that assays which detect a region in
the ORF2-3 junction are more sensitive and robust than
assays relying on ORF2, probably since this region seems
to be less conserved between the HEV genotypes [14].
Because of the fulminant course with progressive acute
liver injury and the immune cell infiltrate observed inindicate focal necrosis, which is typical for acute liver injury.
Figure 2 Liver histology of acute hepatitis E. Acute lobular hepatitis with signs of regeneration; cholestatic hepatitis was also present, in this
section represented by proliferating neoductuli.
Figure 3 Laboratory data and HEV PCR results after and before steroid treatment. Course of laboratory data and HEV PCR before and after
starting immunosuppressive treatment; grey bars represent duration of steroid treatment; prednisolone was started with 1 mg per kilogram
bodyweight per day and reduced in a stepwise fashion.
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with prednisolone was started as an emergency treat-
ment to decelerate liver injury caused by ongoing hepa-
titis. At the time the diagnosis of HEV was established,
we decided to continue steroid treatment because trans-
aminases declined, liver function restored, and viral load
resolved.
Immunosuppressive treatment for acute viral hepatitis
E seems to be counterproductive and even contraindicated
at first glance. Compromising the immune response
would entail the risk of restraining viral clearance or may
even promote a chronic course of infection. Indeed,
chronic autochthonous HEV infection has been mainly
described for immunocompromised patients, particularly
after solid-organ-transplantation, in patients with haem-
atological malignancies or co-infection with human im-
munodeficiency virus [15]. In addition, chronic hepatitis
E has also been described in patients with immune-
mediated diseases, for example idiopathic CD4-disturbance
or systemic lupus erythematodes under immunosuppres-
sive or immune-modulating treatment [16,17]. However,
the present case demonstrates that short-term steroid
medication might be beneficial in HEV-induced acute liver
injury, especially considering that even in HEV infection
acute liver injury is likely immune-mediated and not due
to the viral replication per se [18]. Along this line, recent
data point at a non-cytopathic, immune-mediated hepato-
cyte damage caused by HEV [19,20]. Further investigations
are certainly necessary to get insight into immune mecha-
nisms caused by HEV in the acute and chronic disease to
deliver adequate therapy for patients.
A full literature research revealed another case report
describing recovery from HEV infection under immuno-
suppressive treatment [21]. In that case, HEV was mis-
diagnosed and treated like acute autoimmune hepatitis.
Taken together, immunosuppressive treatment of the in-
flammatory flare of acute HEV infection most likely does
not hinder viral clearance, but may help to avoid additional
liver damage and avert the need for liver transplantation.
It would be beneficial to identify patients with HEV-
induced acute liver injury who might profit from im-
munosuppression and those who are likely to resolve
HEV infection spontaneously without risk for acute liver
failure. As major limitation for the interpretation of our
case, the favourable outcome might just reflect the nat-
ural course of HEV infection that might have developed
even without steroid treatment. Our patient presented
with major risk factors (regular alcohol consumption
and older age) for a severe course of HEV, which were
identified by Péron et al. [3]. It is tempting to assume
that steroid treatment prevented progression to enceph-
alopathy. Still, we cannot rule out that absence of hep-
atic encephalopathy reflects the benign natural clinical
course in this patient and is not a result of steroidtreatment. If autochthonous HEV infection becomes ful-
minant, high-dose steroids might be a supportive treat-
ment, potentially even additive to ribavirin that has
already been used successfully in some case reports
[11,12]. Ribavirin has also been applied as treatment of
acute autochthonous HEV infection on pre-existing
chronic liver disease [22].
This case highlights the possibility of steroid treatment
as a therapeutic rescue in patients with hepatitis E. Fur-
ther studies are required to evaluate whether steroid
treatment has a supportive role for patients with HEV-
induced acute liver injury and improves their spontan-
eous outcome. At least, steroid treatment does not seem
to impair viral clearance. Therefore, steroid use should
not be delayed in severe acute immune-mediated hepa-
titis if HEV infection is assumed and diagnostic test re-
sults are pending.
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